MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO - UC-IMM-2101

nicancer0 个研究点目标入组 646 人开始时间: 2024年6月12日最近更新: 2024年8月21日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 646

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Patients must have signed a written informed consent form prior to any trial specific procedures., Evidence of post-menopausal status, or negative urinary or serum pregnancy test for premenopausal patients, Both sexually active women of childbearing potential and males (and their female partners ) patients must agree to use adequate contraception method for the duration of the study treatment and after completing treatment according to the most recent version of the IO SmPC., Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up., Patient must be affiliated to a Social Security System, Patient aged =18 years old., Metastatic disease (or locally advanced disease not suitable for local treatment) of initial tumor histologically confirmed including : lung cancer, renal cell cancer, head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, hepatocellular carcinoma, melanoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, cervical cancer, gastric/gastro-oesophageal junction adenocarcinoma, basal cell carcinoma or squamous skin carcinoma., Patients in partial or complete response after 6 months of standard immunotherapy (whatever the line of therapy) according to the RECIST v1.1 or PERCIST v1.0 criteria (confirmed by local radiological assessment). For metastatic melanoma only patients in partial response. Patients with metastatic or advanced cancer treated by immunotherapy as maintenance therapy can be included without any lesion at IO initiation. In this case, response after 6 months of standard immunotherapy will be evaluated by the nonappearance of a new lesion., Eligible to maintain the same standard IO treatment, Patient with ECOG performance status =1., Patients with brain metastases are allowed, provided they are stable according to the following definitions: treated with surgery or stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases., Patients treated by IO previously combined with chemotherapy are allowed, Patients with TKI-IO or pemetrexed-IO or bevacizumab-IO are allowed

排除标准

•Metastatic melanoma in complete response, Metastatic renal cell carcinoma with IMDC favourable-risk treated TKI/IO combination, Hematologic malignancies (leukaemia, myeloma, lymphoma…), Active infection requiring systemic therapy., Patients enrolled in another therapeutic study within 30 days before the inclusion in and during MOIO study, Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study., Person deprived of their liberty or under protective custody or guardianship

研究者

发起方

nicancer

相似试验

进行中（未招募）

1 期

EUCTR2021-000615-23-FRICANCER646

招募中

3 期

Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRA

IRCT20210620051639N3Bagheiat-allah University of Medical Sciences10,300

进行中（未招募）

1 期

A trial testing lenalidomide and dexamethasone after standard radiotherapy in patients with solitary bone plasmacytoma who are at a high risk of relapse

EUCTR2015-001355-76-GBniversity College London140

已完成

3 期

A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanomaStage IV melanomaMalignant neoplasm of skinCancer

ISRCTN72807124Department of Health (UK)

进行中（未招募）

1 期

Immunogenicity, Tolerability, and Manufacturing Consistency study of a Multivalent HPV, VLP vaccinePrevention of cervical, vulvar, and vaginal cancers and related precancers, externalgenital lesions, Pap test abnormalities, and persistent infection caused by humanpapillomavirus (HPV) Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.MedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862

EUCTR2009-011617-25-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,2,000